Angiogenic factors are elevated in overweight and obese individuals

International Journal of Obesity

Volumn 29, Issue 11, 2005, Pages 1308-1314

  Silha, J V ^a   Krsek, M ^b   Sucharda, P ^b   Murphy, L J ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Angiogenesis; Growth factors; Metastasis

Indexed keywords

ANGIOGENIC FACTOR; ANGIOGENIN; ANGIOPOIETIN 2; ENDOSTATIN; SCATTER FACTOR; VASCULOTROPIN; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 2;

ADULT; ARTICLE; BODY MASS; CANCER; DIET RESTRICTION; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OBESITY; PRIORITY JOURNAL; RISK ASSESSMENT; SERUM; SEX DIFFERENCE;

ADIPONECTIN; ADULT; ANALYSIS OF VARIANCE; ANGIOGENIC PROTEINS; ANGIOPOIETIN-2; ENDOSTATINS; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; INSULIN RESISTANCE; LEPTIN; LINEAR MODELS; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; RIBONUCLEASE, PANCREATIC; SEX CHARACTERISTICS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR D; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 27944453623     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/sj.ijo.0802987     Document Type: Article

References (49)

1. Rupnick MA, Panigrahy D, Zhang CY, Dallabrida SM, Lowell BB, Langer R, Folkman MJ. Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci USA 2002; 99: 10730-10735.
2. Amling CL, Riffenburgh RH, Sun L, Moul JW, Lance RS, Kusuda L, Sexton WJ, Soderdahl DW, Donahue TF, Foley JP, Chung AK, McLeod DG. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 2004; 22: 439-445.
3. Daniell HW, Tam E, Filice A. Larger axillary metastases in obese women and smokers with breast cancer - an influence by host factors on early tumor behavior. Breast Cancer Res Treat 1993; 25: 193-201.
4. Freedland SJ, Aronson WJ, Kane CJ, Presti Jr JC, Amling CL, Elashoff D, Terris MK. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol 2004; 22: 446-453.
5. Mick GJ, Wang X, McCormick K. White adipocyte vascular endothelial growth factor: regulation by insulin. Endocrinology 2002; 143: 948-953.
6. Rahmi N, Saulnier R, Nakamura T, Park M, Elliott B. Role of hepatocyte growth factor in breast cancer: a novel mitogenic factor secreted adipocytes. DNA Cell Biol 1994; 13: 1189-1197.
7. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 941-946.
8. Brakenhielm E, Veitonmaki N, Cao R, Kihara S, Matsuzawa Y, Zhivotovsky B, Funahashi T, Cao Y. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci USA 2004; 101: 2476-2481.
9. Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes 2003; 52: 1779-1785.
10. Silha JV, Krsek M, Skrha JV, Sucharda P, Nyomba BL, Murphy LJ. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol 2003; 149: 331-335.
11. Morishita R, Nakamura S, Hayashi S, Aoki M, Matsushita H, Tomita N, Yamamoto K, Moriguchi A, Higaki J, Ogihara T. Contribution of a vascular modulator, hepatocyte growth factor (HGF), to the pathogenesis of cardiovascular disease. J Atheroscler Thromb 1998; 4: 128-134.
12. Yoshitomi Y, Kojima S, Umemoto T, Kubo K, Matsumoto Y, Yano M, Sugi T, Kuramochi M. Serum hepatocyte growth factor in patients with peripheral arterial occlusive disease. J Clin Endocrinol Metab 1999; 84: 2425-2428.
13. Chou E, Suzuma I, Way KJ, Opland D, Clermont AC, Naruse K, Suzuma K, Bowling NL, Vlahos CJ, Aiello LP, King GL. Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic States: a possible explanation for impaired collateral formation in cardiac tissue. Circulation 2002; 105: 373-379.
14. Miyazawa-Hoshimoto S, Takahashi K, Bujo H, Hashimoto N, Saito Y. Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects. Diabetologia 2003; 46: 1483-1488.
15. Rehman J, Cosidine RV, Bovenkerk JE, Li J, Slavens CA, Jones RM, March KL. Obesity is associated with increased levels of circulating hepatocyte growth factor. J Am Coll Cardiol 2003; 41: 1408-1413.
16. Mathews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentration in man. Diabetalogia 1985; 28: 412-419.
17. Saad MF, Damani S, Gingerich RL, Riad-Gabriel MG, Kahn A, Boyadjian R, Jinagouda SD, el-Tawil K, Rude RK, Kamdar V. Sexual dimorphism in plasma leptin concentration. J Clin Endocrinol Metab 1997; 82: 579-584.
18. Gavrila A, Chan JL, Yiannakouris N, Kontogianni M, Miller LC, Orlova C, Mantzoros CS. Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans: cross-sectional and interventional studies. J Clin Endocrinol Metab 2003; 88: 4823-4831.
19. Mantzoros CS, Moschos S, Avramopoulos I, Kaklamani V, Liolios A, Doulgerakis DE, Griveas I, Katsilambros N, Flier JS. Leptin concentrations in relation to body mass index and the tumor necrosis factor-alpha system in humans. J Clin Endocrinol Metab 1997; 82: 3408-3413.
20. Hausman GJ, Richardson RL. Adipose tissue angiogenesis. J Anim Sci 2004; 82: 925-934.
21. Liu L, Meydani M. Angiogenesis inhibitors may regulate adiposity. Nutr Rev 2003; 61: 384-387.
22. Cui Y, Whiteman MK, Langenberg P, Sexton M, Tkaczuk KH, Flaws JA, Bush TL. Can obesity explain the racial difference in stage of breast cancer at diagnosis between black and white women? J Womens Health Gend Based Med 2002; 11: 527-536.
23. Maehle BO, Tretli S, Skjaerven R, Thorsen T. Premorbid body weight and its relations to primary tumour diameter in breast cancer patients; its dependence on estrogen and progesterone receptor status. Breast Cancer Res Treat 2001; 68: 159-169.
24. Marret H, Perrotin F, Bougnoux P, Descamps P, Hubert B, Lefranc T, Le Floch O, Lansac J, Body G. Low body mass index is an independent predictive factor of local recurrence after conservative treatment for breast cancer. Breast Cancer Res Treat 2001; 66: 17-23.
25. Derossis AM, Fey JV, Cody III HS, Borgen PI. Obesity influences outcome of sentinel lymph node biopsy in early-stage breast cancer. J Am Coll Surg 2003; 197: 896-901.
26. Katoh A, Watzlaf VJ, D'Amico F. An examination of obesity and breast cancer survival in post-menopausal women. Br J Cancer 1994; 70: 928-933.
27. Giovannucci L, Rimm EB, Liu Y, Leitzmann M, Wu K, Stampfer MJ, Willett WC. Body mass index and risk of prostate cancer in US health professionals. J Natl Cancer Inst 2003; 95: 1240-1244.
28. Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, Gaudino G, Tamagnone L, Coffer A, Comoglio PM. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 1992; 119: 629-641.
29. Nishimura M, Ikeda T, Ushiyama M, Nanbu A, Kinoshita S, Yoshimura M. Increased vitreous concentrations of human hepatocyte growth factor in proliferative diabetic retinopathy. J Clin Endocrinol Metab 1999; 84: 659-662.
30. Sato T, Yoshinouchi T, Sakamoto T, Fujieda H, Murao S, Sato H, Kobayashi H, Ohe T. Hepatocyte growth factor (HGF): a new biochemical marker for acute myocardial infarction. Heart Vessels 1997; 12: 241-246.
31. Yamamoto Y, Kohara K, Tabara Y, Miki T. Association between carotid arterial remodeling and plasma concentration of circulating hepatocyte growth factor. J Hypertension 2001; 19: 1975-1979.
32. Stacker SA, Achen MG. The vascular endothelial growth factor family: signalling for vascular development. Growth Factors 1999; 17: 1-11.
33. Keck RG, Berleau L, Harris R, Keyt BA. Disulfide structure of the heparin binding domain in vascular endothelial growth factor: characterization of posttranslational modifications in VEGF. Arch Biochem Biophys 1997; 344: 103-113.
34. Kondo T, Vicent D, Suzuma K, Yanagisawa M, King GL, Holzenberger M, Kahn CR. Knockout of insulin and IGF-1 receptors on vascular endothelial cells protects against retinal neovascularization. J Clin Invest 2003; 111: 1835-1842.
35. Witzenbichler B, Asahara T, Murohara T, Silver M, Spyridopoulos I, Magner M, Principe N, Kearney M, Hu JS, Isner JM. Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. Am J Pathol 1998; 153: 381-394.
36. Marconcini L, Marchio S, Morbidelli L, Cartocci E, Albini A, Ziche M, Bussolino F, Oliviero S. c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro. Proc Natl Acad Sci USA 1999; 96: 9671-9676.
37. Jeltsch M, Kaipainen A, Joukov V, Meng X, Lakso M, Rauvala H, Swartz M, Fukumura D, Jain RK, Alitalo K. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 1997; 276: 1423-1425.
38. Veikkola T, Jussila L, Makinen T, Karpanen T, Jeltsch M, Petrova TV, Kubo H, Thurston G, McDonald DM, Achen MG, Stacker SA, Alitalo K. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J 2001; 20: 1223-1231.
39. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K, Detmar M. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001; 7: 192-198.
40. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, Jackson DG, Nishikawa S, Kubo H, Achen MG. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001; 7: 186-191.
41. Kou B, Li Y, Zhang E, Zhu G, Wang X, Li Y, Wang YZ, Shi YA. In vivo inhibition of tumor angiogenesis by a soluble VEGFR-2 fragment. Exp Mol Pathol 2004; 76: 129-137.
42. Moenner M, Gusse M, Hatzi E, Badet J. The widespread expression of angiogenin in different human cells suggests a biological function not only related to angiogenesis. Eur J Biochem 1994; 226: 483-489.
43. Adams SA, Subramanian V. The angiogenins: an emerging family of ribonuclease related proteins with diverse cellular functions. Angiogenesis 1999; 3: 189-199.
44. Mochizuki Y, Nakamura T, Kanetake H, Kanda S. Angiopoietin 2 stimulates migration and tube-like structure formation of murine brain capillary endothelial cells through c-Fes and c-Fyn. J Cell Sci 2002; 115: 175-183.
45. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997; 277: 55-60.
46. Etoh T, Inoue H, Tanaka S, Barnard GF, Kitano S, Mori M. Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. Cancer Res 2001; 61: 2145-2153.
47. Wickstrom SA, Alitalo K, Keski-Oja J. An endostatin-derived peptide interacts with integrins and regulates actin cytoskeleton and migration of endothelial cells. J Biol Chem 2004; 279: 20178-20185.
48. Abdollahi A, Hahnfeldt P, Maercker C, Grone HJ, Debus J, Ansorge W, Folkman J, Hlatky L, Huber PE. Endostatin's antiangiogenic signaling network. Mol Cell 2004; 13: 649-663.
49. Seida A, Wada J, Kunitomi M, Tsuchiyama Y, Miyatake N, Fujii M, Kira S, Takahashi K, Shikata K, Makino H. Serum bFGF levels are reduced in Japanese overweight men and restored by a 6-month exercise education. Int J Obes Relat Metab Disord 2003; 27: 1325-1331.